Suggested Readings

Diagnosis and management of multiple myeloma: a review. 

Cowan AJ, et al. JAMA. 2022;327(5):464-477.

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. 

Rajkumar SV. Am J Hematol. 2022;97(8):1086-1107.

Targeting BCMA in multiple myeloma. 

Tan CR, Shah UA. Curr Hematol Malig Rep. 2021;16(5):367-383. 

The emerging therapeutic landscape of relapsed/refractory multiple myeloma.

Tanenbaum B, et al. Ann Hematol. 2023;102(1):1-11.

Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group.

Palumbo A, et al. J Clin Oncol. 2015;33(26):2863-2869.

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.

Morris EC, et al. Nat Rev Immunol. 2022;22(2):85-96.

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.      

Ludwig H, et al. Lancet Oncol. 2023;24(6):e255-e269.

Idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Munshi NC, et al. N Engl J Med. 2021;384(8):705-716.

Ide-cel or standard regimens in relapsed and refractory multiple myeloma.

Rodriguez-Otero P, et al. N Engl J Med. 2023;388(11):1002-1014.

Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma.

Jagganath S, et al. J Clin Oncol. 2025;43(25):2766-2771.

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma.

San-Miguel J, et al. N Engl J Med. 2023;389(4):335-347.

Teclistamab plus daratumumab in relapsed or refractory multiple myeloma.

Costa LJ, et al. N Engl J Med. 2026;394(8):739-752. 

Bispecific antibodies in multiple myeloma: a concise review of current treatments.

Ansari AM, et al. Cancer Invest. 2026;44(9):933-944.

Treatment decisions in multiple myeloma.

Mouhieddine TH, et al. N Engl J Med. 2026;395(10):992-1008. 

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: current evidence and emerging strategies.

Pan D, et al. Cancer. 2026;132(17):e70597. 

Related activities
 
0.75 CME/CE

Top 10 Questions From Oncology NPs and PAs

Optimizing Use of BsAb and CAR T-Cell Therapy in Multiple Myeloma Management

Faculty: Amie Fonder, PA-C
Release: 11/13/2026
Expiration: 11/13/2027